Biognosys expands cooperation with Thermo Fisher

The biotech Biognosys from Schlieren in the canton of Zurich and Thermo Fisher Scientific, an American supplier of laboratory equipment based in the U.S. state of Massachusetts, are expanding their existing co-marketing collaboration. According to a press release, the agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics to offer combined solutions. Biognosys deploys Thermo Fisher Scientific instruments for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its instruments and workflows.

“Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application,” said Lukas Reiter, Chief Technology Officer of Biognosys. This combined offering helps researchers “look at every angle of the proteome”, so they can unlock discoveries and transform clinical research. Andreas Huhmer, Senior Director Life Sciences Research at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth.”

Biognosys is a leader in proteomics, the decoding of the proteome, meaning all proteins expressed in a cell, tissue or organism at a specific point of time. For this, the company develops analytics procedures, software and kits. It is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) with headquarters in the Bio-Technopark Schlieren-Zurich.